Resolve M Therapeutics, Inc. has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organisation, Johnson & Johnson Innovation – JJDC, Inc., and General Inception.
Leveraging differentiated insights and capabilities from Nir Hacohen’s lab at the Broad Institute, Resolve M’s platform aims to harness the pro-resolving potential of the MS1 (myeloid state 1) cell to restore homeostasis in patients with chronic inflammatory and autoimmune disorders, without completely shutting down the immune system. This approach offers a potentially safer and more effective therapeutic option than is currently available. Pro-resolving mechanisms restore tissues to homeostasis after an infection or injury during the resolution phase of inflammation.
Hacohen, core member of the Broad Institute and professor of medicine at Harvard Medical School said: “Our findings of a defined myeloid cell state with suppressive functions provides a platform for induction, or modulation, of immune cells and their functions for therapeutic purposes in diverse inflammatory conditions.”
Engaging the pro-resolving response has long been an area of active investigation because of its transformative potential. However, prior efforts in this field have focused primarily on resolving lipid mediators, which have not met expectations in the clinic. Johnson & Johnson Innovation – JJDC Inc. and General Inception recognized the potential of Hacohen’s platform to drive pro-resolving cells in vivo and in vitro, enabling mechanistic understanding of myeloid cell function. By leveraging JJDC’s early-stage company build approach, General Inception will be more strongly positioned to move from Hacohen’s science to clinical proof of concept.
Venkat Reddy, CSO of General Inception, said: “By targeting the body’s innate resolution mechanisms with translatable biomarkers, we can rapidly validate our approach in patients and make real-time adjustments. This integrated model, merging world-class science, purpose-built infrastructure, and deep operational expertise, allows us to shorten development timelines, accelerating our journey to deliver transformative treatments for patients with chronic inflammatory diseases.”
Resolve M aims to build the world’s first comprehensive pro-resolution platform for target identification, validation, and drug discovery in inflammatory diseases.